Loading…
Ind-Swift Laboratories (INDSWFTLAB)₹349.05+3.59%Pharmaceuticals
Ind-Swift Laboratories is compared with the 10 closest in size in Pharmaceuticals (229 companies in the industry). It has a P/E of 36.1 against a peer median of 71.7, and ROCE of 5.0% against a peer median of 5.0%, and latest-quarter sales growth of 51.1% against a peer median of 46.0%. By market cap it is #6 of 11 in this set.
As of · Peer set: 10 closest in size in Pharmaceuticals
| Company | M-cap (₹ Cr) | P/E | ROCE % | ROE % | Debt / equity | Div. yield % | Sales (₹ Cr) | Net profit (₹ Cr) | Qtr sales growth % | Qtr profit growth % | Compare |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gujarat Themis Biosyn | 4,138 | 88.5 | — | — | — | 0.2 | 165 | 47 | 22.3 | 22.5 | vs INDSWFTLAB |
| Kwality Pharmaceuticals | 4,011 | 49.3 | 24.0 | 22.9 | 0.39 | 0.0 | 503 | 67 | 46.0 | 116.4 | vs INDSWFTLAB |
| Shukra Pharmaceuticals | 3,618 | 110.9 | 36.9 | 28.9 | 0.06 | 0.0 | 57 | 22 | 379.2 | 1,191.1 | vs INDSWFTLAB |
| Unichem Laboratories | 3,584 | 11.7 | 4.0 | 3.2 | 0.18 | 0.0 | 2,200 | 253 | 20.0 | — | vs INDSWFTLAB |
| Solara Active Pharma Sciences | 3,143 | 91.9 | 5.0 | −0.1 | 0.41 | 0.0 | 1,374 | −7 | 32.8 | — | vs INDSWFTLAB |
| Ind-Swift Laboratories | 3,037 | 36.1 | 5.0 | 4.0 | 0.01 | 0.0 | 649 | 43 | 51.1 | 325.2 | — |
| Hikal | 2,772 | — | 4.0 | 2.9 | 0.57 | 0.3 | 1,714 | −49 | 6.0 | — | vs INDSWFTLAB |
| Dishman Carbogen Amcis | 2,616 | 162.2 | 3.0 | 1.6 | 0.46 | 0.0 | 2,927 | 97 | −4.3 | −352.0 | vs INDSWFTLAB |
| Fredun Pharmaceuticals | 2,507 | 55.0 | 21.1 | 15.7 | 0.80 | 0.0 | 637 | 33 | 89.9 | 85.7 | vs INDSWFTLAB |
| Sakar Healthcare | 2,284 | 53.4 | 12.0 | 10.0 | 0.13 | 0.0 | 251 | 30 | 49.9 | 119.8 | vs INDSWFTLAB |
| Sai Parenterals | 2,237 | 156.2 | 5.0 | 4.9 | 0.96 | 0.0 | 382 | 14 | 435.6 | 455.2 | vs INDSWFTLAB |
| Peer median | 3,037 | 71.7 | 5.0 | 4.5 | 0.40 | 0.0 | 637 | 33 | 46.0 | 118.1 |
Listed companies closest to Ind-Swift Laboratories in Pharmaceuticals include Gujarat Themis Biosyn, Kwality Pharmaceuticals, Shukra Pharmaceuticals, Unichem Laboratories, Solara Active Pharma Sciences, Hikal, Dishman Carbogen Amcis, Fredun Pharmaceuticals.
Gujarat Themis Biosyn, with a market cap of ₹4,138 Cr.
Ind-Swift Laboratories trades at a P/E of 36.1; the median of its peer set is 71.7. A P/E above or below the median is a description, not a judgement on value.
Ind-Swift Laboratories' return on capital employed is 5.0%, below the peer median of 5.0%.